INTERVENTION 1:	Intervention	0
Ondansetron Therapy	Intervention	1
ondansetron	CHEBI:7773	0-11
Patients receive 16mg ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.	Intervention	2
ondansetron	CHEBI:7773	22-33
peripheral	HP:0030646	85-95
blood	UBERON:0000178	96-101
ondansetron: Given IV	Intervention	3
ondansetron	CHEBI:7773	0-11
survey administration: Correlative studies	Intervention	4
management of therapy complications: Ondansetron IV	Intervention	5
ondansetron	CHEBI:7773	37-48
Inclusion	Eligibility	0
Autologous PBSC transplant patient	Eligibility	1
patient	HADO:0000008,OAE:0001817	27-34
English-speaking	Eligibility	2
Planned cryopreserved PBSC infusion at the SCCA outpatient clinic	Eligibility	3
Exclusion	Eligibility	4
History of prior autologous transplant	Eligibility	5
history	BFO:0000182	0-7
Non-English-speaking	Eligibility	6
Planned cryopreserved PBSC infusion at the UWMC inpatient unit	Eligibility	7
Infusion of cryopreserved PBSC that are thawed and washed to remove DMSO prior to infusion	Eligibility	8
dmso	CHEBI:28262,BAO:0000118	68-72
Allergy or adverse reaction to ondansetron	Eligibility	9
allergy	HP:0012393	0-7
ondansetron	CHEBI:7773	31-42
Outcome Measurement:	Results	0
Reduction in Rates of Nausea or Vomiting After Ondansetron (Compared to FHCRC Historical Rates)	Results	1
nausea	HP:0002018	22-28
vomiting	HP:0002013	32-40
ondansetron	CHEBI:7773	47-58
Nausea Multinational Association of Supportive Care in Cancer Antiemesis Toolâ„¢ (MAT). Increased MAT scores represent worse outcome (score 0-10). Vomiting represented as present or absent.	Results	2
nausea	HP:0002018	0-6
cancer	DOID:162	55-61
vomiting	HP:0002013	145-153
present	PATO:0000467	109-116
present	PATO:0000467	156-163
present	PATO:0000467	169-176
absent	PATO:0000462	180-186
Time frame: Baseline up to 120 minutes	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ondansetron Therapy	Results	5
ondansetron	CHEBI:7773	17-28
Arm/Group Description: Patients receive 16mg ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.	Results	6
ondansetron	CHEBI:7773	45-56
peripheral	HP:0030646	108-118
blood	UBERON:0000178	119-124
ondansetron: Given IV	Results	7
ondansetron	CHEBI:7773	0-11
survey administration: Correlative studies	Results	8
management of therapy complications: Ondansetron IV	Results	9
ondansetron	CHEBI:7773	37-48
Overall Number of Participants Analyzed: 49	Results	10
Measure Type: Count of Participants	Results	11
Unit of Measure: Participants  MAT score >2 on arrival and pre-ondansetron: 23  46.9%	Results	12
Baseline MAT score >2 prior to first ASCT infusion: 9  18.4%	Results	13
MAT score increases >2 by end of infusion: 12  24.5%	Results	14
Number of patients that vomited: 9  18.4%	Results	15
Adverse Events 1:	Adverse Events	0
Total: 0/49 (0.00%)	Adverse Events	1
